Combined treatment with dacarbazine, cisplatin and interferon α in metastatic melanoma;Association dacarbazine, cisplatinium et interferon α dans le traitement du melanome metastatique

Annales de Dermatologie et de Venereologie

Volumn 123, Issue 9, 1996, Pages 538-542

  Tessier, M H ^a   Mansat, E ^a   Legoux, B ^a   Litoux, P ^a   Dreno, B ^a  

^a CLINIQUE DERMATOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CISPLATIN; DACARBAZINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; FEMALE; HUMAN; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; NAUSEA; PERIPHERAL NEUROPATHY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 0029836245     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Fletcher WS, Green S, Fletcher JR, Dana B, Jewell W, Townsend RA. Evaluation of cis-platinium and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study. Am J Clin Oncol 1988;11:589-93.
2. Icl F, Karaogus H, Dincol D, Gunel L, Demirkazic A. Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin. J Surg Oncol 1991;48:199-201.
3. Fletcher WS, Daniels DS, Sondak VK, Dana B, Townsend R, Hynes HE et al. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group Study. Am J Clin Oncol 1993;16:359-62.
4. Steffens TA, Bajorin DF, Chapman PB, Lovett DR, Cody-Johnson BV, Templeton MA et al. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer 1991;65:1230-7.
5. Murren JR, Derosa W, Durivage HJ, Davis C, Makuch R, Portlock CS. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991;67:1514-7.
6. Luger SM, Kirkwood JM, Ernstoff MS, Vlock DR. High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst 1990;82:1934-7.
7. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-86.
8. Oken MM, Creen RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Group. Am J Clin Oncol 1982;5:649-55.
9. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991;9:1403-8.
10. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12:806-1.